T2D experts weigh in
on TRAJENTA® & JENTADUETO®.
With CARMELINA®, the simplicity of TRAJENTA® is reinforced by the reinforced safety profile, established efficacy and the convenience of one dose once daily
Simplicity of Trajenta® within the DPP4i class: established efficacy, established safety profile, and convenience of one dose once daily
TRAJENTA®: Proven efficacy.
Trajenta® consistently lowers HbA1c in line with other DPP4i
Trajenta®'s efficacy is fully on par with other DPP4 inhibitors
TRAJENTA®: Safety profile - Cardiovascular outcome trial program.
CAROLINA® is the only CVOT within the DPP4i class to assess the cardiovascular safety of linagliptin versus an active comparator
CARMELINA® is unique in the DPP4i class as it includes T2D patients with high cardiovascular risk and, in many instances, with impaired renal function
TRAJENTA®: Safety profile - CARMELINA® Results.
With CARMELINA®, linagliptin demonstrated a long-term cardiovascular safety profile in patients with T2D and showed no increase in risk of hospitalisation for heart failure
CARMELINA® is the only DPP4i CVOT that included a kidney-related secondary end point. The study showed no difference in outcome between TRAJENTA® and placebo
Trajenta® can be used in a broad range of T2D patients, independent of kidney function, whenever a DPP4i is needed
JENTADUETO®: Powerful HbA1c reductions for high baseline
Prof. Per-Henrik Groop
SPC metformin with linagliptin: the only DPP4i that does not require dose reduction when kidney function declines
Prof. Stefano Del Prato
Linagliptin has demonstrated high efficacy in T2D patients with high baseline HbA1c
55-year-old male; HbA1c 8%; on metformin; normal kidney function; Trajenta® is an appropriate option when a DPP4i is needed